Straits Times Index
3,240.58 +49.87 (+1.56%) Nikkei
26,739.03 +336.19 (+1.27%) Hang Seng
20,717.24 +596.56 (+2.96%) FTSE 100
7,389.98 +87.24 (+1.19%) BTC-USD
29,209.28 -874.08 (-2.91%) CMC Crypto 200
652.12 -21.25 (-3.16%)
Repare Therapeutics Inc. (RPTX)
| Previous close | 8.57 |
| Open | 8.68 |
| Bid | 5.00 x 800 |
| Ask | 13.37 x 800 |
| Day's range | 8.06 - 8.78 |
| 52-week range | 8.06 - 35.75 |
| Volume | |
| Avg. volume | 171,204 |
| Market cap | 354.006M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.08 |
| Earnings date | 10 Aug 2022 - 15 Aug 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 36.22 |
- Business Wire
Repare Therapeutics to Participate at the 2022 Guggenheim Synthetic Lethality Day
CAMBRIDGE, Mass. & MONTREAL, May 09, 2022--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate in a fireside chat at the virtual 2022 Guggenheim Synthetic Lethality Day on Monday, May 16, 2022 at 9:00 a.m. Eastern Time.
- Zacks
Repare Therapeutics Inc. (RPTX) Reports Q1 Loss, Misses Revenue Estimates
Repare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of 6.74% and 80.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
Repare Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results
CAMBRIDGE, Mass. & MONTREAL, May 05, 2022--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2022.
